Literature DB >> 19212333

GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines.

A Furuhata1, M Murakami, H Ito, S Gao, K Yoshida, S Sobue, R Kikuchi, T Iwasaki, A Takagi, T Kojima, M Suzuki, A Abe, T Naoe, T Murate.   

Abstract

Although oncogenic functions and the clinical significance of Wilms tumor 1 (WT1) have been extensively studied in acute leukemia, the regulatory mechanism of its transcription still remains to be determined. We found a significant correlation among the amounts of WT1, GATA-1 and GATA-2 mRNAs from leukemia and solid tumor cell lines. Overexpression and small interfering RNA (siRNA) transfection experiments of GATA-1 and GATA-2 showed that these GATA transcription factors could induce WT1 expression. Promoter analysis showed that the 5' promoter did not explain the different WT1 mRNA levels between cell lines. The 3' enhancer, especially the distal sites out of six putative GATA binding sites located within the region, but not the intron 3 enhancer, were essential for the WT1 mRNA level. Electrophoretic mobility shift assay (EMSA) showed both GATA-1 and GATA-2 bound to these GATA sites. Besides acute leukemia cell lines, solid tumor cell lines including, TYK-nu-cPr also showed a high level of WT1 mRNA. We showed that GATA-2 expression is a determinant of WT1 mRNA expression in both TYK-nu-cPr cells and HL60 cells without GATA-1 expression. Taken together, these results suggest that GATA-1 and/or GATA-2 binding to a GATA site of the 3' enhancer of WT1 played an important role in WT1 gene expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212333     DOI: 10.1038/leu.2009.13

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

1.  The clinical significance of the alternative Wilms tumor gene overexpression-hypermethylation signature in acute myeloid leukemia.

Authors:  M El Bordiny; A Al-Ghandour; R A Abo Elwafa; O Fayed
Journal:  Clin Transl Oncol       Date:  2018-11-30       Impact factor: 3.405

2.  TGF-β-activated kinase 1 is crucial in podocyte differentiation and glomerular capillary formation.

Authors:  Sung Il Kim; So-Young Lee; Zhibo Wang; Yan Ding; Nadeem Haque; Jiwang Zhang; Jing Zhou; Mary E Choi
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

3.  Down-regulation of PROS1 gene expression by 17beta-estradiol via estrogen receptor alpha (ERalpha)-Sp1 interaction recruiting receptor-interacting protein 140 and the corepressor-HDAC3 complex.

Authors:  Atsuo Suzuki; Naomi Sanda; Yuhri Miyawaki; Yuta Fujimori; Takayuki Yamada; Akira Takagi; Takashi Murate; Hidehiko Saito; Tetsuhito Kojima
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

4.  TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.

Authors:  Toru Sakairi; Yoshifusa Abe; Jeffrey B Kopp
Journal:  Nephrol Dial Transplant       Date:  2011-03-04       Impact factor: 5.992

5.  Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.

Authors:  Dinesh Kumar Sahu; Neetu Singh; Mumani Das; Jiledar Rawat; Devendra Kumar Gupta
Journal:  Pediatr Surg Int       Date:  2022-09-15       Impact factor: 2.003

6.  Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia.

Authors:  M Celton; A Forest; G Gosse; S Lemieux; J Hebert; G Sauvageau; B T Wilhelm
Journal:  Leukemia       Date:  2014-02-11       Impact factor: 11.528

7.  Classification of human genomic regions based on experimentally determined binding sites of more than 100 transcription-related factors.

Authors:  Kevin Y Yip; Chao Cheng; Nitin Bhardwaj; James B Brown; Jing Leng; Anshul Kundaje; Joel Rozowsky; Ewan Birney; Peter Bickel; Michael Snyder; Mark Gerstein
Journal:  Genome Biol       Date:  2012-09-26       Impact factor: 13.583

8.  miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level.

Authors:  Shen-meng Gao; Chong-yun Xing; Chi-qi Chen; Si-si Lin; Pei-hong Dong; Fu-jun Yu
Journal:  J Exp Clin Cancer Res       Date:  2011-12-01

9.  Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.

Authors:  Amy Guillaumet-Adkins; Julia Richter; Maria D Odero; Juan Sandoval; Xabi Agirre; Albert Catala; Manel Esteller; Felipe Prósper; María José Calasanz; Ismael Buño; Mi Kwon; Franck Court; Reiner Siebert; David Monk
Journal:  J Hematol Oncol       Date:  2014-01-09       Impact factor: 17.388

10.  Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Authors:  Massimo Alfano; Paola Cinque; Guido Giusti; Silvia Proietti; Manuela Nebuloni; Silvio Danese; Silvia D'Alessio; Marco Genua; Federica Portale; Manuela Lo Porto; Pravin C Singhal; Maria Pia Rastaldi; Moin A Saleem; Domenico Mavilio; Joanna Mikulak
Journal:  Sci Rep       Date:  2015-09-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.